Rigel Pharmaceuticals Inc. (New) RIGL

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

RIGL hizo una agrupación de acciones (split inverso) de 1:10 el 27 de junio de 2024: cada 10 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 28 sept

  Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

  Arvinas announced the first patient dosing in a Phase 1/2 clinical trial of ARV-6723, an oral PROTAC designed to degrade HPK1 for advanced solid tumors. The drug is Arvinas' first immuno-oncology candidate and the first HPK1 PROTAC degrader to enter clinical trials in the US. Preclinical data showed potent HPK1 degradation, enhanced immune activity, and antitumor effects as monotherapy and in combination with anti-PD-1 therapy, including activity in anti-PD-1-resistant models.

  

• GlobeNewswire Inc. 1 sept

  Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia

  Knight Therapeutics announced that it received regulatory approval from Colombia's health authority (INVIMA) for TAVALISSE (fostamatinib disodium hexahydrate) to treat adult patients with chronic immune thrombocytopenia (ITP). The company plans to launch the drug in Colombia in the first half of 2027, following its May 2026 launch in Mexico and an expected Q4 2026 launch in Brazil.

  

• GlobeNewswire Inc. 1 sept

  Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® en Colombie

  Knight Therapeutics Inc. (TSX: GUD) announced regulatory approval from Colombia's INVIMA for TAVALISSE® (fostamatinib disodium heptahydrate) to treat adult patients with chronic immune thrombocytopenia (ITP). The approval marks a significant milestone in Knight's Latin American expansion strategy following its 2022 licensing agreement with Rigel Pharmaceuticals. The company plans to launch TAVALISSE in Colombia in H1 2027, following launches in Mexico (May 2026) and Brazil (Q4 2026).

  

• GlobeNewswire Inc. 29 jul

  Onco360® Has Been Selected as a National Pharmacy Partner for VEPPANU™ (vepdegestrant)

  Onco360, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Rigel Pharmaceuticals for VEPPANU (vepdegestrant), an FDA-approved PROTAC estrogen receptor degrader for treating ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. In the Phase 3 VERITAC-2 trial, vepdegestrant demonstrated a 43% reduction in disease progression or death risk compared to fulvestrant in patients with ESR1 mutations.